[Acute hypopyon uveitis with rifabutin therapy of systemic Mycobacterium avium complex (MAC) infection in AIDS].
BACKGROUND
Hypopyon-uveitis has been identified as a dosage-dependent side effect in patients with acquired immunodeficiency syndrome who are treated for Mycobacterium avium complex (MAC) infection with systemic rifabutin.


METHODS
We report a 38-year-old female AIDS patient with bilateral hypopyon uveitis under therapy with rifabutin in combination with clarithromycin and indinavir.


RESULTS
At the time of presentation of the bilateral hypopyon uveitis the patient was treated with rifabutin (300 mg/day), clarithromycin (1000 mg/day) and ethambutol (1000 mg/day) for an M. avium complex infection. Also, the patient received the protease inhibitor indinavir. The rifabutin dose was reduced to 150 mg/day. Hypopyon and inflammation resolved under therapy with steroids.


CONCLUSIONS
The concomitant use of rifabutin, clarithromycin, and protease inhibitors may lead to hypopyon uveitis. Reduction of dosage of rifabutin (150 mg/day) and treatment with topical steroids are required.
Augenklinik, Universität München.
U C
UC
Schaller
G
G
Michl
F D
FD
Goebel
V
V
Klauss
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007500:Iritis / Q000139:chemically induced* / Q000175:diagnosis; D015269:Mycobacterium avium Complex / Q000187:drug effects; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D017828:Rifabutin / Q000008:administration & dosage / Q000009:adverse effects*; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000175:diagnosis
D017828:Rifabutin
Akute Hypopyon-Uveitis unter Rifabutin-Therapie einer systemischen Mycobacterium avium complex (MAC)-Infektion bei AIDS.